AR and lymphoma: For example, EZH2 inhibitors show potent antitumor activity in lymphomas with EZH2 gain-of-function mutations (104), yet in some NEPC models, EZH2 blockade did not promote lineage reversal back to an AR-driven luminal sensitive state, but rather a forward differentiation to a more terminal ARSI-resistant neuroendocrine state (26).